Together we will change the way infections are treated, improve care, and save lives. 

diagnosis AND management

of bloodstream infections.

How HelixBind is Changing Care

Revolutionizing the

HelixBind's proprietary Resistance and Pathogen Identification (RaPID) platform provides rapid detection and unequivocal identification of bloodstream infections, direct from a whole blood specimen and without the need for blood culture.  


RaPID results will allow physicians to quickly select the optimal antimicrobial intervention, targeted for the specific infection, and to monitor the effectiveness of that treatment throughout care. Rapid and accurate identification of bloodstream infections will improve care and save lives. 


HelixBind in the News

HelixBind is growing and actively looking for talented individuals.

Explore HelixBind Technology

The Challenge of Sepsis

Sepsis, the body’s severe response to a bloodstream infection, is a leading cause of death. Over 270,000 Americans and 11 million individuals worldwide die from sepsis each year.  These infections progress quickly, but once the causative pathogen is identified, aggressive treatment with the appropriate antimicrobial can save lives. 

Current diagnostic techniques to identify the infection rely on blood cultures, which takes days to provide a result. During the critical first few hours and days of illness, healthcare professionals are forced to treat patients based on their best guess. This leads to poor patient outcomes and reduces the effectiveness of existing drugs by driving antimicrobial resistance among pathogens.

identify the infection faster




Traditional blood culture test


RaPID results may help guide appropriate clinical decisions and select the best treatment options long before culture results become available. 



HelixBind, Inc.
181 Cedar Hill Street
Marlborough, MA 01752 


For general inquiries, contact us at:


For partnerships and business development: